Loading...

CCR

CCM

ICECURE MEDICAL LTD

(ICCM)

2025 6-K

Class Action Update

6 May '26

Shareholder Meeting Notice

22 Apr '26

Revenue Increase Report

21 Apr '26

Securities Offering

27 Mar '26

Positive Study Results

25 Mar '26

Management Changes

24 Mar '26

Board Resignation

17 Mar '26

Financial Report Released

17 Mar '26

FDA Approval Announcement

11 Mar '26

Cryoablation Recommendation

9 Mar '26

6-K Filing

2 Mar '26

Cryoablation Study Update

23 Feb '26

CFO Resignation

9 Feb '26

Record Sales Report

12 Jan '26

Equity Agreement Update

9 Jan '26

Shareholder Meeting

8 Jan '26

Record Sales Expected

17 Dec '25

Cryoablation Studies

10 Dec '25

Patent Notice Received

5 Dec '25

Special Meeting Notice

2 Dec '25

Financial Results Report

19 Nov '25

Regulatory Approval

18 Nov '25

Nasdaq Notification

14 Nov '25

Management Change

10 Nov '25

Successful Treatment Report

3 Nov '25

Management Change

17 Oct '25

FDA Approval Granted

3 Oct '25

Positive Results

30 Sep '25

Positive Clinical Results

22 Sep '25

Patent Allowance News

18 Sep '25

Regulatory Approval

15 Sep '25

Shareholder Meeting Update

4 Sep '25

Pain Relief Breakthrough

4 Sep '25

Shareholder Meeting

20 Aug '25

Financial Results Report

13 Aug '25

Meeting Update

1 Aug '25

Rights Offering Closed

1 Aug '25

Shareholder Meeting Notice

28 Jul '25

Positive Clinical Data

25 Jul '25

Shareholder Meeting Notice

16 Jul '25

Financial Update

10 Jul '25

Preliminary Financial Results

3 Jul '25

Rights Offering Notice

25 Jun '25

Patent Allowance Notice

9 Jun '25

Q1 2025 Results

28 May '25

Loan Agreement

21 May '25

Shareholder Meeting Approval

15 May '25

FDA Development Update

30 Apr '25

Shareholder Meeting Notice

10 Apr '25

Sales Growth Report

27 Mar '25

FDA Progress Update

20 Mar '25

Cryoablation Studies

18 Mar '25

Cryoablation Approval

17 Mar '25

Patient Satisfaction Report

10 Mar '25

Regulatory Filing

24 Feb '25

FDA Anticipation

4 Feb '25

Regulatory Approval Filing

27 Jan '25

Equity Distribution Agreement

13 Jan '25

Sales Growth Report

13 Jan '25

Market Compliance Achieved

6 Jan '25

Patent Notice Issued

3 Jan '25

Board Appointment

30 Dec '24

Kidney Tumor Report

5 Dec '24

Sales Growth Report

26 Nov '24

Patent Notice Approved

25 Nov '24

FDA Approval Update

8 Nov '24

Patent Notice Received

21 Oct '24

Global Studies Announcement

7 Oct '24

Trial Results Published

24 Sep '24

ProSense Success Rate

16 Sep '24

FDA Meeting Announcement

12 Sep '24

Patent Allowance Granted

28 Aug '24

Sales Growth Report

20 Aug '24

Breast Cancer Success

14 Aug '24

Positive Study Results

7 Aug '24

Meeting Canceled

6 Aug '24

Cryoablation Success

22 Jul '24

Nasdaq Notification

19 Jul '24

Shareholder Meeting Notice

16 Jul '24

Study Results Report

9 Jul '24

FDA Clearance Granted

1 Jul '24

FDA Panel Review

4 Jun '24

Sales Growth Report

28 May '24

Annual Meeting Results

21 May '24

Study Results Released

7 May '24

Shareholder Meeting Notice

15 Apr '24

Clinical Trial Results

15 Apr '24

Sales Increase Report

3 Apr '24

FDA Filing Update

2 Apr '24

Positive Study Results

19 Mar '24

Patent Notice

12 Mar '24

New Treatment Announcement

4 Mar '24

Tumor Reduction Study

26 Feb '24

FDA Appeals Granted

30 Jan '24

Equity Distribution Agreement

12 Jan '24

Compliance Regained

12 Jan '24

Sales Increase Report

10 Jan '24

External Links:

SEC

IceCure Medical Ltd. announced on October 3, 2025, that it received FDA marketing authorization for its ProSense® Cryoablation treatment aimed at low-risk breast cancer in women aged 70 and above, marking a significant advancement in minimally invasive care.

AI Assistant

ICECURE MEDICAL LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.